<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068302</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000321392</org_study_id>
    <secondary_id>CHP-755</secondary_id>
    <secondary_id>CHP-IRB-2002-12-3086</secondary_id>
    <nct_id>NCT00068302</nct_id>
  </id_info>
  <brief_title>Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Trial Of Sirolimus In Relapsed/Refractory Leukemia And Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Childhood Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as sirolimus use different ways to stop cancer&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of sirolimus in&#xD;
      treating young patients with relapsed or refractory acute leukemia or non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of sirolimus in pediatric patients with refractory&#xD;
           or relapsed acute leukemia or non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the dose-limiting toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the trough levels produced by this drug in these patients.&#xD;
&#xD;
        -  Determine the anti-leukemia/lymphoma activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive oral sirolimus once daily on days 1-21. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of sirolimus until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruiting/enrolling participants halted prematurely but potentially will resume&#xD;
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as assessed by Common Toxicity Criteria (CTC) toxicity criteria after the first course of treatment</measure>
    <time_frame>within 21 days following administration of sirolimus</time_frame>
    <description>Subjects will be assessed for toxicity on days 3, 7 and 21</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response as assessed by radiologic scans after each course of treatment</measure>
    <time_frame>day 21</time_frame>
    <description>Response will be assessed on day 21 of cycle 1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>3-6 subjects will be enrolled into each dose level</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL) OR acute myeloid leukemia (AML)&#xD;
&#xD;
                    -  At least 25% blasts in the bone marrow&#xD;
&#xD;
                    -  Recurrent or refractory disease&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
                    -  Second or greater relapse as determined by physical or radiological evidence&#xD;
&#xD;
          -  Disease for which there is no known curative therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  21 and under&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100% (patients over 10 years of age)&#xD;
&#xD;
          -  Lansky 50-100% (patients 10 years of age and under)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3 (transfusion independent)*&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL (may receive red blood cells (RBC) transfusions)* NOTE:&#xD;
             *Patients with ALL, AML, and NHL with tumor metastatic to bone marrow, with&#xD;
             granulocytopenia, anemia, and/or thrombocytopenia are eligible, but will not be&#xD;
             evaluable for hematological toxicity&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  alanine aminotransferase (ALT) no greater than 5 times normal&#xD;
&#xD;
          -  Albumin at least 2 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine based on age, as follows:&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (5 years of age and under)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (6 to 10 years of age)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (11 to 15 years of age)&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (over 15 years of age) OR&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Shortening fraction at least 28% by echocardiogram OR&#xD;
&#xD;
          -  Ejection fraction at least 50% by gated radionuclide&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to ingest oral medication&#xD;
&#xD;
          -  No known allergy to sirolimus, tacrolimus, or other mammalian target of rapamycin&#xD;
             (mTOR) inhibitors&#xD;
&#xD;
          -  No uncontrolled active infection&#xD;
&#xD;
               -  Fungal disease must be stable for at least 2 weeks prior to study entry&#xD;
&#xD;
               -  Documented negative blood cultures prior to study entry for patients with&#xD;
                  bacteremia&#xD;
&#xD;
          -  No active graft-versus-host disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  More than 1 week since prior hematopoietic growth factors except for epoetin alfa&#xD;
&#xD;
          -  At least 7 days since prior biologic antineoplastic agents&#xD;
&#xD;
          -  At least 3 months since prior bone marrow or stem cell transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from all prior chemotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)&#xD;
&#xD;
          -  Prior hydroxyurea within the past 2 weeks is allowed provided peripheral blast count&#xD;
             has been stable or rising for at least 3 days&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior corticosteroids within the past 2 weeks are allowed provided peripheral blast&#xD;
             count has been stable or rising for at least 3 days&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior craniospinal radiotherapy or radiation to the pelvis of&#xD;
             50% or more&#xD;
&#xD;
          -  At least 4 weeks since prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy, except for emergent situations or persistent&#xD;
             extramedullary disease with resolution of bone marrow disease&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational antineoplastic drugs&#xD;
&#xD;
          -  No concurrent administration of any of the following:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Tacrolimus&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Diltiazem&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Rheingold, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

